#StridesPharma allots approximately 1.51 lakh shares of face value of Rs 10 each to Karuna Business Solutions

#USFDA issues Establishment Inspection Report for #StridesPharma’s #Puducherry facility

#StridesPharma | Intent is to bring in #CDMO business of under the company. Under proposed plan, #Stelis will house additional group #businesses

Here’s more 👇 https://t.co/YdOnBriTvk

#StridesPharma | Intent is to bring in #CDMO business under the company. Under proposed plan, #Stelis will house additional group #businesses

Here’s more 👇 https://t.co/IrUJmXzHbU https://t.co/WELwOClkSR

#StridesPharma | In-principle looking to combine the CDMO business under the Strides umbrella https://t.co/6VXkY5HuOO

#StridesPharma gets US FDA nod for Sevelamer Carbonate Tablets

💊Sevelamer Carbonate helps prevent Hypocalcemia
caused by Elevated Phosphorus

💊Sevelamer Carbonate Tablets, 800 mg has a market
size of $181 m as per IMS

#StridesPharma Arm Gets US FDA Nod For Theophylline Extended-Release Tablets

Alert | Theophylline Tablet Is Used In Treatment Of Chronic Asthma & Other Chronic Lung Diseases

#StridesPharma gets shareholder nod for creation of #OneSource

Alert | OneSource is a specialty pharma contract development & manufacturing organisation

#StridesPharma reports Q2 earnings

Net Profit At ₹93 Cr Vs Loss Of ₹131 Cr (YoY)

Revenue up 20.2% At ₹1,201 Cr Vs ₹999.4 Cr (YoY)

EBITDA up 54% At ₹235.7 Cr Vs ₹153 Cr (YoY)

Margin At 19.6% Vs 15.3% (YoY)